/PRNewswire/ SanReno Therapeutics, a clinical-stage company specializing in the discovery, development, and commercialization of innovative therapies for.
Sanreno Therapeutics Announces Acquisition By Novartis In Pivotal Transaction To Bring Forward Transformative Therapeutics In Kidney Disease menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
AUR200, a potent recombinant fusion protein, has a clinically validated MOA with a high affinity for targeting both BAFF and APRIL
Upon FDA clearance of the IND, AUR 200 will be studied in a.
Aurinia Pharmaceuticals Inc. announced the submission of its Investigational New Drug application to the U.S. Food and Drug Administration for AUR200, a potential next generation therapy for B-cell.
Aurinia Pharmaceuticals (AUPH) Submits IND Application to the FDA for AUR 200 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.